title: Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy.
abstract: OBJECTIVE
  The aim of this study was to describe a case of angiographically documented foveal avascular zone (FAZ) enlargement after intravitreal bevacizumab following vitrectomy and intravitreal bevacizumab treatment of a diabetic patient.
  
  
  METHODS
  This study was done as a case report.
  
  
  RESULTS
  A 40-year-old diabetic man was treated with a pars plana vitrectomy and intravitreal bevacizumab for a nonclearing vitreous hemorrhage. Despite successful surgery, the postoperative best-corrected visual acuity was not improved. FAZ area had increased from 1.48 mm(2) preoperatively to 1.96 mm(2) postoperatively (24.5% increase).
  
  
  CONCLUSIONS
  Although intravitreal bevacizumab is an effective modality for diabetic retinopathy, it may deteriorate pre-existing retinal ischemia.
authors.affiliation: The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Sung Jun
authors.initials: SJ
authors.lastname: Lee
authors.forename: Hyoung Jun
authors.initials: HJ
authors.lastname: Koh
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000601:surgery; D005451:Fluorescein Angiography; D005584:Fovea Centralis / Q000098:blood supply / Q000473:pathology*; D006801:Humans; D006984:Hypertrophy; D007267:Injections; D008297:Male; D014821:Vitrectomy; D014822:Vitreous Body; D014823:Vitreous Hemorrhage / Q000188:drug therapy* / Q000601:surgery
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab